Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms  by Meissner, Torsten et al.
FEBS 28803 FEBS Letters 576 (2004) 27–30Ratjadone and leptomycin B block CRM1-dependent nuclear export
by identical mechanismsTorsten Meissnera, Eberhard Krauseb, Uwe Vinkemeiera,*
aAbteilung Zellul€are Signalverarbeitung, Leibniz-Forschungsinstitut f€ur Molekulare Pharmakologie, Freie Universit€at Berlin,
Robert-R€ossle-Str. 10, 13125 Berlin, Germany
bArbeitsgruppe Massenspektrometrie, Leibniz-Forschungsinstitut f€ur Molekulare Pharmakologie, Freie Universit€at Berlin,
Robert-R€ossle-Str. 10, 13125 Berlin, Germany
Received 22 July 2004; revised 16 August 2004; accepted 30 August 2004
Available online 11 September 2004
Edited by Felix WielandAbstract Research on the export of proteins and nucleic acids
from the nucleus to the cytoplasm has greatly gained from the
discovery that the actinobacterial toxin leptomycin B (LMB)
speciﬁcally inactivates the export receptor chromosomal region
maintenance 1 (CRM1). Recently, it was shown that myxobac-
terial cytotoxins, named ratjadones (RATs), also bind to CRM1
and inhibit nuclear export. However, the reaction mechanism of
RATs was not resolved. Here, we show that LMB and RAT A
employ the same molecular mechanism to inactivate CRM1.
Alkylation of residue Cys528 of CRM1 determines both LMB
and RAT sensitivity and prevents nuclear export of CRM1 cargo
proteins.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Communication between the cell nucleus and the cytoplasm
frequently requires shuttling of signal transducers such as
Smads or Stats between both compartments [1,2]. It is well
established now that a group of related proteins, called kary-
opherins, mediates many of the necessary translocation pro-
cesses (reviewed in [3]). It is a hallmark of karyopherin-assisted
translocation that the cargo molecules harbour loosely con-
served localisation signals in their primary sequence. Gener-
ally, these signals are necessary and suﬃcient for the
karyopherins to recognise their cargo. For nuclear import,
stretches of positively charged residues termed nuclear locali-
sation signal are required, whereas nuclear export signals
(NESs) consist of hydrophobic residues, predominantly leu-
cines (reviewed in [4]). The karoypherins are also termed im-
portins or exportins according to the direction of transport* Corresponding author. Fax: +49-30-94793-179.
E-mail address: vinkemeier@fmp-berlin.de (U. Vinkemeier).
Abbreviations: CRM1, chromosomal region maintenance 1; GFP,
green ﬂuorescent protein; GST, glutathione S-transferase; LMB,
leptomycin B; NES, nuclear export signal; RAT, ratjadone; Smad, a
combination of the gene names from C. elegans, Sma, and D.
melanogaster, Mad; Stat, signal transducer and activator of transcrip-
tion
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doi:10.1016/j.febslet.2004.08.056that they support. At present, there are no pharmacological
inhibitors available to inactivate importins. Karyopherin-
mediated nuclear export, on the other hand, is readily blocked
by the actinobacterial biocide leptomycin B (LMB), which was
isolated from Streptomyces sp. [5]. The discovery of the export
blocking activity of LMB has tremendously advanced the
study of protein nucleocytoplasmic shuttling and lead to the
discovery of the exportin chromosomal region maintenance 1
(CRM1). CRM1 was originally identiﬁed as a protein re-
sponsible for maintaining the chromosome structure in the
yeast Schizosaccharomyces pombe [6]. Later, it was found that
CRM1 acted also as the NES receptor in both lower and
higher eukaryotes (reviewed in [7]). Recognition of the NES by
CRM1 is speciﬁcally inhibited by LMB, which binds cova-
lently to a single sulfhydryl group of CRM1 [8,9]. The modi-
ﬁcation of Cys529 of Crm1 from S. pombe and of the
homologous Cys528 from H. sapiens was demonstrated to
block association of CRM1 with the NES-containing cargo,
thus inhibiting nuclear protein export. It has been recognised
over the last years that NES-mediated nuclear export by
CRM1 is a universal and conserved mechanism by which the
subcellular localisation of proteins is determined in cells (re-
viewed in [7]). Very recently, a group of polyketides from
myxobacterium Sorangium cellulosum was also implicated in
the CRM1-dependent export of proteins from the nucleus.
Hauser and colleagues convincingly demonstrated that the
ratjadones (RATs), which are structurally related to LMB,
inhibit the formation of nuclear export complexes by the direct
binding of RAT to CRM1 ([10]; for a review on RATs, see
[11]). However, the mechanism by which the RATs inactivate
CRM1 was not resolved. Here, we demonstrate that RAT A
blocks protein export by covalently binding to Cys528 of hu-
man CRM1. Thus, both LMB and RATs inhibit nuclear
protein export by identical reaction mechanisms.2. Materials and methods
2.1. Cell culture
HeLaS3 cells were grown on glass coverslips at 37 C in a humidiﬁed
5% CO2 atmosphere in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
containing 10% (v/v) foetal calf serum (FCS; Biochrom, Berlin) and
antibiotics. For microinjections, the coverslips were transferred into
3.5 cm dishes ﬁlled with 1 ml culture medium without or with the in-
dicated export inhibitor. LMB (Sigma) and RAT A (a kind gift of Dr.
Markus Kalesse, Universit€at Hannover) were dissolved in methanolblished by Elsevier B.V. All rights reserved.
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10 ng/ml. Transient transfections were performed by using Lipofecta-
mine-plus (Life Technologies) according to the manufacturer’s
instructions.
2.2. Plasmid construction
pGST-green ﬂuorescent protein (GFP) and pGST-NES-GFP con-
taining a canonical NES from human Stat1 (residues 365–427) were
described [12]. A mammalian expression vector encoding a fusion
protein of GFP with a Stat1-derived NES activity (aa 365–427) was
constructed by PCR-ampliﬁcation of the cDNA of NES-GFP from
pGST-NES-GFP using the following primers: 50-ATATATGGAT-
CCAGATAAAGATGTGAATGAG-30 and 50-CGCCCCGACACC-
CGCCAACACCC-30 (restriction sites underlined). After restriction
digestion with the enzymes BamHI and EcoRI, the resulting fragment
encoding the Stat1 NES was inserted into the BglII/EcoRI sites of the
vector pEGFP-C3 (Clontech) to yield pGFP-NES.The cDNAs forwild-
type CRM1 and the CRM1 mutant Cys528 to Ser (TGT>TCT) were
kindly providedbyDr.BryanR.Cullen (DukeUniversity,Durham) and
Dr. ShigekiMiyamoto (University ofWisconsin), respectively. To allow
for indirect immunodetection of CRM1, FLAG-tagged expression
constructs were prepared as follows. The wild-type and mutant CRM1
coding sequences were ampliﬁed by PCR using the primer pair
50-ATTATAGGATCCATGCCAGCAATTATGACAATG-30 and
50-ATATTAGGATCCCATCACACATTTCTTCTGG-30. The result-
ing cDNA was digested with BamHI and inserted into the BglII sites of
the vector pFLAG, which was derived from pStat1-Flag [12] after re-
moving the Stat1 coding region by digestionwithEcoRI. pFLAGallows
the expression of aC-terminal FLAGepitope (DYKDDDDK) followed
by a stop codon. PCR was carried out with Vent-proofreading enzyme
(NEB). The constructs were conﬁrmed by DNA sequencing across the
mutated codons and the restriction sites used for cloning.
2.3. Microinjections and ﬂuorescence analysis
Preparation of the glutathione S-transferase (GST)–GFP fusion
proteins and microinjections were performed as described in Begitt
et al. [13]. In brief, the fusion proteins were expressed in Escherichia coli
BL21 and aﬃnity-puriﬁed using glutathione-sepharose beads (Amer-
sham). The recombinant proteins (1 lg/ll in microinjection buﬀer: 20
mMHEPES–OH, pH 7.5, 110 mMKAc, 0.5 mM EDTA, 5 mMDTT)
were injected into the nucleus of HelaS3 cells using a Transjector 5246
(Eppendorf). They were co-injected with TRITC-coupled BSA (0.2 lg/
ll; Sigma) to indicate the site of injection. Approximately ﬁfty cells
were injected within 15 min. After injection, the cells were incubated at
37 C for another hour before ﬁxation for 15 min in 4% (v/v) form-
aldehyde in PBS. Nuclei were stained with Hoechst 33258 (5 lg/ml in
PBS; Sigma) for 3 min. After washing three times with PBS and once
with H2O, the cells were mounted in Dako ﬂuorescent mounting me-
dium (DakoCytomation). Cells were examined by conventional ﬂuo-
rescence microscopy using an Axioplan 2 Imaging system (Zeiss).
2.4. Immunocytochemistry
For immunodetection of FLAG-tagged CRM1, a mouse monoclo-
nal antibody directed against the FLAG epitope (M2; Sigma) was
employed. Twenty-four hours after transfection, the cells were ﬁxed forFig. 1. RAT A causes nuclear accumulation of a NES-containing reporter pr
or with a GFP expression vector (D–F). Twenty-four hours after transfectio
untreated (A, D). Subsequently, cells were ﬁxed with formaldehyde and stain
depicted in green.15 min in 4% (v/v) formaldehyde/PBS, then permeabilised with 0.2%
(v/v) Triton X-100 and blocked for 30 min with 10% FCS (v/v) in PBS.
Incubation with the primary antibody at a dilution of 1:1000 was done
in 10% FCS in PBS at 4 C overnight. After repeated washing with
PBS, the cells were incubated for 1 h at RT with a Cy3-conjugated
donkey anti-mouse IgG antibody (Jackson Immunoresearch) at a di-
lution of 1:2000 in 10% FCS in PBS. Following Hoechst staining and
extensive washing with PBS, the cells were mounted as described
above.
2.5. Mass spectrometric analysis
Peptide labelling was essentially performed as described by Kudo
et al. [9]. One lg of a human CRM1 peptide (residues 513–530; Bio-
synthan, Berlin) containing the conserved Cys528 was treated with or
without 10 lg RAT in 15 ll labelling buﬀer (20 mM Tris–HCl, pH 7.5,
100 mM NaCl). Following overnight incubation at 37 C, the samples
were analysed by mass spectrometry. Samples were diluted with 5 ll of
1% (v/v) formic acid in water and puriﬁed over a C18 reversed-phase
microcolumn, ZipTip (Millipore), according to the manufacturer’s
manual. Peptides were eluted from the ZipTips with 5 ll of 70% (v/v)
acetonitrile, 0.25% (v/v) formic acid in water. Mass spectrometric
analyses of unmodiﬁed and modiﬁed CRM1 peptides were performed
as previously described [14,15]. Brieﬂy, matrix-assisted laser desorp-
tion/ionisation mass spectrometry (MALDI-MS) measurements were
performed on a Voyager-DE STR BioSpectrometry Workstation
MALDI-TOF mass spectrometer (Perseptive Biosystems, Inc.) using
an alpha-cyano-4-hydroxycinnamic acid matrix. In order to verify the
sequences of CRM1(513–530) and the position of modiﬁcation, MS/
MS analyses were performed by nanoelectrospray quadrupole
TOF (Q-Tof Ultima, Manchester, UK) and MALDI TOF-TOF
(4700 Proteomics Discovery System; Applied Biosystems) mass
spectrometry.3. Results and discussion
At ﬁrst, we demonstrated that RAT A can revert the accu-
mulation in the cytoplasm of a protein that contains a ca-
nonical NES. A reporter protein consisting of GFP fused to a
canonical NES, amino acids 365–427 of human Stat1 [12], was
expressed in mammalian cells. The steady state localisation of
this protein is cytoplasmic, contrary to GFP with a pancellular
or predominantly nuclear localisation (compare Fig. 1A and
D). Due to their small size (30 kD), these proteins are capable
of passing through the nuclear pore by free diﬀusion [16].
Treatment of cells expressing GFP for 60 min with 10 ng/ml
LMB or 10 ng/ml RAT A was without detectable inﬂuence on
the subcellular distribution of GFP (Fig. 1E and F). On con-
trary, the same treatment abolished the cytoplasmic accumu-
lation of GFP-NES, which was now found in both the nucleus
and the cytoplasm (Fig. 1B and C).otein. HelaS3 cells were transiently transfected with pGFP-NES (A–C)
n, cells were treated with LMB (B, E) or RAT A (C, F) for 1 h or left
ed with Hoechst 33258 to indicate the nuclei (blue). The GFP signal is
Fig. 3. RAT A covalently binds to Cys528 of a CRM1-peptide. Syn-
thetic human CRM1 (residues 513–530) that contains Cys528 was
incubated with RAT A for 24 h at 37 C and analysed by MALDI–
TOF-MS. The peaks with m/z 2103.06 (theoretical m/z 2103.19) and
2559.40 (theoretical m/z 2559.48; see also enlargement) correspond,
respectively, to the unmodiﬁed and RAT A-alkylated hCRM1 se-
quence 513EKRFLVTVIKDLLGLCEQ530.
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inhibitory eﬀect of LMB and RAT A on nuclear export. Here,
a recombinant reporter protein consisting of a fusion of GST
and GFP was puriﬁed from bacteria and subsequently injected
into the nucleus of HeLa cells. Its large size (55 kD) precluded
free diﬀusion across the nuclear envelope (Fig. 2A). The in-
sertion of cDNA coding for a Stat1 NES activity (aa 365–427)
between the genes coding for GST and GFP resulted in a
bacterial expression construct that yielded the export reporter
protein GST–NES-GFP. As is shown in Fig. 2B, a 1 h incu-
bation period following nuclear microinjection of the export
reporter resulted in its steady state cytoplasmic accumulation.
Preincubation of the cells with RAT A or LMB for 3 h before
microinjection completely blocked the subsequent nuclear ex-
port of the NES fusion protein (Fig. 2C and D). These results
conﬁrm the previous observation that both bacterial metabo-
lites inhibit the nuclear export of NES-containing proteins at a
similar concentration [10].
A major unanswered question concerns the reaction mech-
anisms of RATs and LMB, both of which target CRM1. The
molecular mechanism of CRM1 inactivation was identiﬁed as
the addition of LMB through its a,b unsaturated d-lactone to
the sulfhydryl group of residue Cys528. To investigate whether
Cys528 was targeted also by RATs, which similar to LMB
contain an unsaturated lactone, we followed a procedure that
was employed by Kudo et al. [9] to demonstrate the modiﬁ-
cation by LMB of Cys528 of human CRM1. An 18mer peptide
(residues 513–530) corresponding to the stretch of conserved
hydrophobic amino acids in the N-terminal ﬂanking region of
Cys528 (residues 517–528) was synthesised and reacted with-
out or with RAT A. Mass spectrometric analysis of the un-
reacted material revealed a mass peak of the unmodiﬁed
CRM1 peptide at m/z 2103.06. After the incubation with RAT
A, an additional peak at m/z 2559.40 was detected whichFig. 2. RAT A blocks the nuclear export of a NES-containing reporter
protein. The indicated GST–GFP fusion proteins were injected into the
nuclei of HelaS3 cells. One hour after microinjection, cells were ﬁxed
and stained with Hoechst 33258 to show the nuclei. The site of injec-
tion is given by the coinjected injection marker (TRITC-BSA). The
GFP signal is shown in green. In C and D, cells were preincubated with
the indicated export inhibitor for 3 h before microinjection.corresponds to the adduct of the peptide and RAT A (Fig. 3).
The amino acid sequence and the site of RAT modiﬁcation
was conﬁrmed by tandem MS. The evidence for the alkylation
of Cys528 comes from the presence of unmodiﬁed N-terminal
b ions and the neutral loss of the RAT moiety during frag-
mentation (data not shown).
We next analysed a mutant of human CRM1 with a serine
mutation in position 528. Cysteine528 is conserved between S.
pombe and humans, which are LMB-sensitive, but not in
LMB-insensitive organisms such as Sac. cerevisiae. Moreover,
replacement of this cysteine by serine resulted in insensitivity
of S. pombe CRM1 towards LMB [8,9]. For our experiments,
Flag-tagged expression constructs of wild-type or mutant hu-
man CRM1 were co-expressed with GFP-NES in HeLa cells.
As was described before for NIH3T3 cells [17], CRM1 was
localised mainly intranuclear or at the nuclear rim. Strongly
overexpressing cells displayed also cytoplasmic staining. In this
respect, no diﬀerences were observed between mutant and
wild-type CRM1 (Fig. 4 and data not shown). Moreover, the
localisation of CRM1 was not sensitive towards LMB or RAT
(Fig. 4). On contrary, treatment of cells with either LMB or
RAT A precluded the cytoplasmic accumulation of GFP-NES
in cells expressing wild-type CRM1 (Fig. 4A) and a pancellular
distribution of the reporter protein resulted (Fig. 4C and E).
Expectedly, expression of the Ser528 mutant of CRM1 ren-
dered cells insensitive to the activity of LMB, since the cyto-
plasmic accumulation of the NES-containing reporter
persisted (Fig. 4B and D). Importantly, the identical pheno-
type was observed also after treatment with RAT A in the cells
expressing the mutant CRM1 (Fig. 4F). Thus, we conclude
that both LMB and RAT inhibit protein transportation in vivo
by targeting residue Cys528 of CRM1. Given their identical
and highly speciﬁc modes of molecular action, we propose that
RAT A and LMB can be used interchangeably in the study of
protein export from the nucleus.
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